Product Description
HEC-169096 is a drug candidate from Sunshine Lake Pharma for the treatment of advanced solid tumors. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05451602)
Mechanisms of Action: RET Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sunshine Lake Pharma
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description

Countries in Clinic: China
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Non-Small-Cell Lung Cancer|Small Cell Lung Cancer|Thyroid Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
HEC169096-ST-101 | P2 |
Recruiting |
Thyroid Cancer|Small Cell Lung Cancer|Non-Small-Cell Lung Cancer |
2025-07-30 |
57% |